MyFinsight
Home
Blog
About
Proceeds from exercise of
employee stock options
$2,600K
(18471.43%↑ Y/Y)
Proceeds from employee
stock purchase plan
$611K
(67.40%↑ Y/Y)
Net cash provided by
financing activities
$3,211K
(747.23%↑ Y/Y)
Net decrease in
cash, cash...
-$69,763K
(54.92%↑ Y/Y)
Canceled cashflow
$3,211K
Stock-based compensation
expense
$5,970K
(-41.42%↓ Y/Y)
Accrued expenses and
other current...
$2,210K
(143.53%↑ Y/Y)
Depreciation
$1,914K
(-54.13%↓ Y/Y)
Prepaid expenses and
other assets
-$1,340K
(-178.23%↓ Y/Y)
Defined benefit plan
liability
-$36K
(96.24%↑ Y/Y)
Proceeds from maturities
of marketable...
$51,937K
(-39.20%↓ Y/Y)
Net cash used in
operating activities
-$44,114K
(45.00%↑ Y/Y)
Net cash used in
investing activities
-$28,860K
(61.47%↑ Y/Y)
Canceled cashflow
$11,470K
Canceled cashflow
$51,937K
Net loss
-$43,397K
(-225.46%↓ Y/Y)
Deferred revenue
-$8,968K
(91.61%↑ Y/Y)
Purchases of marketable
securities
$76,074K
(-51.56%↓ Y/Y)
Accounts payable
-$1,493K
(87.53%↑ Y/Y)
Net accretion of
discounts/premiums on marketable...
-$975K
(44.79%↑ Y/Y)
Right-of-use assets and
operating lease...
-$440K
(-3.04%↓ Y/Y)
Other receivables
$311K
(-85.84%↓ Y/Y)
Purchases of property and
equipment
$4,723K
(43.91%↑ Y/Y)
Back
Back
Cash Flow
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)
source: myfinsight.com